|
| Bayer would have more to gain from the approval of Xtend as a LL/Xtend stack is already in the works. If it is approved, Bayer would be able to capitalize on both ends of the trait fees rather than just one if the proposed Bayer/MON deal goes through. Remember, the American farmer is paying <$22 per unit for glyphosate technology. RR1, RR2Y, RR2Y Xtend, RR2Y Xtend/LL, it makes no difference as the common factor is glyphosate which is no more than a glorified grass killer. There would be nothing to gain for Bayer through a delay. In fact, it would hurt future development of soybean traits rather than punish either company. The cost of Xtend herbicides are unknown at this time so comparing herbicide programs is impossible to do at this point. Your point of "our technology" is very limiting as MON has sold that technology to every major breeding program in the industry. Stine, SYT, MON, PHI (and now DOW through the DOW/DuPont merger), all have access to Xtend techology through various agreements. I agree, the technology has been deemed safe by the US and there is no evidence otherwise. However, until it receives global approval, it might as well be poisonous. | |
|
Extend soybeans
